多发性骨髓瘤中的微小残留病：现状与未来展望。
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
作者信息
Mina Roberto, Oliva Stefania, Boccadoro Mario
机构信息
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città dellaSalute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
出版信息
J Clin Med. 2020 Jul 7;9(7):2142. doi: 10.3390/jcm9072142.
Abstract
Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for progression-free survival and overall survival. Several techniques are available for the detection of MRD inside (next-generation sequencing, flow cytometry) and outside (PET/CT, magnetic resonance) the bone marrow, and their complementary use allows a precise definition of the efficacy of anti-myeloma treatments. This review summarizes MRD data and results from previous clinical trials, highlights open issues related to the role of MRD in MM and discusses how MRD could be implemented in clinical practice to inform on patient prognosis and drive therapeutic decisions.
摘要
微小残留病（MRD）检测是一种灵敏的工具，可用于恰当衡量多发性骨髓瘤（MM）治疗所取得的疗效。实现MRD阴性已取代了传统的完全缓解（CR），并被提议作为无进展生存期和总生存期的替代终点。有多种技术可用于检测骨髓内（下一代测序、流式细胞术）和骨髓外（PET/CT、磁共振）的MRD，它们的互补使用能够精确界定抗骨髓瘤治疗的疗效。本综述总结了MRD数据及既往临床试验结果，突出了与MRD在MM中的作用相关的未决问题，并讨论了如何在临床实践中应用MRD来了解患者预后并指导治疗决策。
相似文献
1
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.多发性骨髓瘤中的微小残留病：现状与未来展望。
J Clin Med. 2020 Jul 7;9(7):2142. doi: 10.3390/jcm9072142.
2
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.多发性骨髓瘤的治疗评估和微小残留病灶检测的功能成像。
Int J Mol Sci. 2020 Jul 29;21(15):5406. doi: 10.3390/ijms21155406.
3
MRD Assessment in Multiple Myeloma: Progress and Challenges.多发性骨髓瘤中的微小残留病灶评估：进展与挑战。
Curr Hematol Malig Rep. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5.
4
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?多发性骨髓瘤微小残留病灶的检测：有意义吗？
Curr Hematol Malig Rep. 2019 Feb;14(1):39-46. doi: 10.1007/s11899-019-0497-7.
5
Advances in minimal residual disease monitoring in multiple myeloma.多发性骨髓瘤微小残留病监测的进展
Crit Rev Clin Lab Sci. 2023 Nov;60(7):518-534. doi: 10.1080/10408363.2023.2209652. Epub 2023 May 26.
6
Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.多参数流式细胞术评估多发性骨髓瘤微小残留病
Klin Onkol. 2017 Summer;30(Supplementum2):21-28. doi: 10.14735/amko20172S21.
7
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
8
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.多发性骨髓瘤微小残留病检测的临床应用及未来方向
Front Oncol. 2020 Jan 31;10:1. doi: 10.3389/fonc.2020.00001. eCollection 2020.
9
Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.通过下一代测序检测多发性骨髓瘤中的微小残留病：适应性治疗的前景与挑战
Front Oncol. 2022 Aug 16;12:932852. doi: 10.3389/fonc.2022.932852. eCollection 2022.
10
Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?多发性骨髓瘤临床实践中是否到了引入微小残留病灶的时候？
Clin Cancer Res. 2015 May 1;21(9):2001-8. doi: 10.1158/1078-0432.CCR-14-2841. Epub 2015 Mar 9.
引用本文的文献
1
Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives.多发性骨髓瘤中MRD检测的进展：技术、应用及未来展望
Am J Clin Oncol. 2025 Jul 1;48(7):376-380. doi: 10.1097/COC.0000000000001197. Epub 2025 Apr 11.
2
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.适合移植的新诊断多发性骨髓瘤治疗的临床共识：双盲 Delphi 小组。
Future Oncol. 2024;20(23):1645-1656. doi: 10.1080/14796694.2024.2342228. Epub 2024 May 20.
3
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.II期FORTE试验中微小残留病的前瞻性评估：多参数流式细胞术与下一代测序的直接比较
EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.
4
[Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].[新一代流式细胞术与新一代测序在多发性骨髓瘤微小残留病评估中的比较]
Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):328-332. doi: 10.3760/cma.j.issn.0253-2727.2023.04.011.
5
Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs.多发性骨髓瘤流式细胞术临床报告共识：融合实验室经验与临床需求的多中心协调过程
Cancers (Basel). 2023 Mar 30;15(7):2060. doi: 10.3390/cancers15072060.
6
"Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.下一代流式细胞术评估多发性骨髓瘤可测量/微小残留病的“朋友与敌人”
Front Oncol. 2022 Nov 28;12:1057713. doi: 10.3389/fonc.2022.1057713. eCollection 2022.
7
Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients-A Proof of Concept.多发性骨髓瘤患者液体活检中外泌体中可测量残留疾病生物标志物的检测——概念验证。
Int J Mol Sci. 2022 Nov 8;23(22):13686. doi: 10.3390/ijms232213686.
8
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤中作为无进展生存期替代指标的缓解率和微小残留病灶结果。
PLoS One. 2022 May 12;17(5):e0267979. doi: 10.1371/journal.pone.0267979. eCollection 2022.
9
Smoldering multiple myeloma: Reviewing the rationale for intervention.冒烟型多发性骨髓瘤：干预策略的探讨。
Leuk Lymphoma. 2022 Sep;63(9):2033-2040. doi: 10.1080/10428194.2022.2068008. Epub 2022 May 9.
10
Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study.弥散加权成像联合背景抑制技术在浆细胞瘤分期、预后、形态学、治疗反应及表观弥散系数中的相关性：一项单中心回顾性研究。
PLoS One. 2021 Jul 9;16(7):e0253025. doi: 10.1371/journal.pone.0253025. eCollection 2021.
本文引用的文献
1
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.在新诊断的适合移植的多发性骨髓瘤患者中，采用倾向评分匹配法，比较硼替佐米、沙利度胺和地塞米松（VTd）联合或不联合达雷妥尤单抗（D-VTd）方案在CASSIOPEIA研究中的疗效和安全性，与PETHEMA/GEM研究中VTd方案进行对比。
EJHaem. 2020 Nov 7;2(1):66-80. doi: 10.1002/jha2.129. eCollection 2021 Feb.
2
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.硼替佐米联合地塞米松作为复发/难治性多发性骨髓瘤患者生化复发时的维持治疗或早期再治疗与观察对比：一项随机II期研究
Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.
3
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
4
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
5
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.CD38 靶向免疫 PET 多发性骨髓瘤：从异种移植模型到首例人体成像。
Radiology. 2020 Jun;295(3):606-615. doi: 10.1148/radiol.2020192621. Epub 2020 Apr 7.
6
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.对比基于 MALDI-TOF 质谱分析的外周血和骨髓流式细胞术用于多发性骨髓瘤患者微小残留病灶的检测。
Br J Haematol. 2020 Jun;189(5):904-907. doi: 10.1111/bjh.16443. Epub 2020 Feb 5.
7
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.抗 B 细胞成熟抗原双特异性 T 细胞衔接分子 AMG 420 诱导多发性骨髓瘤产生应答。
J Clin Oncol. 2020 Mar 10;38(8):775-783. doi: 10.1200/JCO.19.02657. Epub 2020 Jan 2.
8
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
9
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.新诊断多发性骨髓瘤研究中微小残留病灶状态作为无进展生存期替代终点的Meta 分析。
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37. doi: 10.1016/j.clml.2019.09.622. Epub 2019 Oct 9.
10
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.基于新一代流式细胞术的多发性骨髓瘤微小残留病灶检测。
J Clin Oncol. 2020 Mar 10;38(8):784-792. doi: 10.1200/JCO.19.01231. Epub 2019 Nov 26.
Zotero 插件